Semaglutide reduces diuretic use and improves symptoms in heart failure patients with preserved ejection fraction.
Weight loss drug, semaglutide, reduces loop diuretic use and dose in heart failure patients with preserved ejection fraction (HFpEF), regardless of diuretic use. Late breaking research presented at Heart Failure 2024 showed semaglutide treatment led to significant improvements in heart failure symptoms, physical limitations, weight loss, and six-minute walk distance compared to placebo in the STEP-HFpEF and STEP-HFpEF DM trials.
May 13, 2024
3 Articles